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Current State of Immune-Based Therapies for Glioblastoma
Michael Lim, MD, Michael Weller, MD, and E. Antonio Chiocca, MD, PhD
OVERVIEW
Glioblastoma is one of the most aggressive solid tumors, and, despite treatment options such as surgery, radiation, and che-
motherapy, its prognosis remains grim. Novel approaches are needed to improve survival. Immunotherapy has proven efficacy for
melanoma, lung cancer, and kidney cancer and is now a focus for glioblastoma. In this article, glioblastoma-mediated immu-
nosuppression will be discussed and two exciting immune approaches, checkpoint inhibitors and viral-based therapies, will be
reviewed.
Glioblastoma has been studied as a paradigmatic tumorfor cancer-associated immunosuppression for more
than 3 decades. Initial observations included the charac-
terization of decreased immune responsiveness of periph-
eral blood cells harvested from patients with glioblastoma.1
This remote effect of a locally growing neoplasm could only
be explained by soluble factors released by the tumor in
sufficient quantities to induce systemic immunosuppression
(Fig. 1). The search for soluble factors produced by cultured
glioblastoma cells resulted in the identification of, among
others, transforming growth factor (TGF)-b as a key im-
munosuppressive cytokine that has remained a therapeutic
target until today. Yet, local application of antisense oli-
gonucleotides failed presumably because of poor target
coverage, whereas systemic application of TGF-b receptor
antagonists has its limits in nonhematologic toxicity. TGF-b
is a member of a large family of cytokines that interacts with
heterodimeric receptors. There are three TGF-b isoforms in
humans that have nonoverlapping functions, at least in
development, as demonstrated in knockout mouse models.
In contrast, the three isoforms are coregulated in glioblas-
tomas, and no isotype-specific roles have been identified so
far in the biology of glioblastoma.2 Other soluble immu-
nosuppressive factor candidates attributed a role in shaping
the immunosuppressive microenvironment in glioblastoma
include interleukin 10 and prostaglandin E2.
Admittedly, it has not been clarified definitively that the
peripheral immunosuppression encountered among patients
with glioblastoma is caused exclusively or even mainly by el-
evated levels of soluble mediators systemically. Alternatively,
it is conceivable that immune modulatory cells that encoun-
ter the glioblastoma microenvironment are forced to de-
velop into an immunosuppressive immune cell population that
indirectly mediates systemic immunosuppression. In fact, it
has recently been recognized that glioblastoma cells are
capable of reshaping the phenotype of tumor-infiltrating
host cells, which comprise a large proportion of cells within
the microenvironment of glioblastoma, to support their
growth and maintain any immunosuppressive milieu.3
In addition to the soluble immunosuppressive molecule
candidates mentioned above, immune-relevant molecules
expressed at the cell surface of glioblastoma have attracted
interest because there is major infiltration of glioblastomas
by host cells, although the cells are mainly of macrophage-
monocyte lineage. These surface molecules include the CD95
ligand, which may induce apoptosis in susceptible cells that
express the receptor, CD95, previously referred to as Fas or
APO-1. In the context of glioblastoma, cellular targets for
CD95-mediated apoptosis are probably mainly T cells. Addi-
tional candidate cell surface molecules with immunosup-
pressive properties, but with uncertain significance in
glioblastoma, include regeneration and tolerance factor (RTF),
lectin-like transcript 1, and HLA-E and HLA-G.4
More recently, major emphasis has been placed on the
aberrant expression of PD-L1 by glioblastoma cells. PD-L1 is
the ligand for PD-1, a cell surface molecule expressedmainly
on T cells now referred to as an immune checkpoint, to-
gether with CTLA-4. These two molecules, PD-1 and CTLA-4,
mediate inactivation of T cells, and antibody-mediated
therapeutic neutralization of these molecules with agents
such as nivolumab or pembrolizumab that target PD-1, or
ipilimumab that targets CTLA-4, can be considered the
greatest innovation in medical oncology in the past decade.5
They are currently being explored as novel agents across the
full spectrum of human cancers and have already been in-
tegrated into the standard of care for malignant melanoma.
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Furthermore, antibodies targeting the ligand PD-L1 rather
than the receptor, such as atezolizumab, also are being ex-
plored in various tumorentities. Theextent that glioblastomas
express PD-L1 in vivo has remained controversial,6 but PD-1
and CTLA-4 inhibition are remarkably active in mouse glioma
models, both as single agents and in combination. Impor-
tantly, inhibition of immune checkpoints probably confers a
nonspecific state of immune activation that will be of benefit
to patients if their particular cancers carry a high mutational
load, rendering them potentially recognizable as altered.
Whether the observed benefit can be translated to glio-
blastoma remains to be clarified. Several clinical trial initiatives
to explore immune checkpoint inhibitors in glioblastoma are
now underway.
Because of disappointing results with traditional cancer
therapy (radiotherapy, chemotherapy, and angiogenesis
inhibition by promising agents, such as VEGF pathway in-
hibitors bevacizumab and cediranib) in this disease, various
approaches to immunotherapy have gained a lot of interest.
As of early 2016, several phase II and phase III clinical trials of
immunotherapy are underway or have already been com-
pleted, including but not limited to (1) the rindopepimut
vaccine that targets epidermal growth factor variant III,
with a completed phase III trial in the newly diagnosed
setting (ACT IV) and encouraging activity in phase II in the
recurrent setting (Re-ACT); (2) the six-candidate peptide
cocktail ICT-107, which is used to generate a vaccine by
ex vivo stimulation of patient-derived dendritic cells, with a
completed randomized phase II trial that indicated activity in
patients who were HLA-A2 positive and a phase III program
scheduled to start in early 2016; and (3) the DCVax phase III
program that is near completion, with high logistical
complexity—it uses autologous tumor to stimulate autol-
ogous dendritic cells.
These treatments likely are most effective with minimal
residual tumor burden, which should be associated with
decreased levels of soluble immunosuppressive factors and
decreased potential for immune cell re-education by bulky
tumor. Accordingly, most recent immunotherapy trials have
been and are now being conducted in highly selected patient
populations in the newly diagnosed setting and among
patients with little or no residual tumor after concomi-
tant temozolomide chemoradiotherapy. Given these de-
velopments, it can be assumed that neurosurgery will be
attributed a larger role not only in newly diagnosed patients
but also in the setting of recurrent disease, if the first de-
finitively positive immunotherapy data become available.
Although removing the source of immunosuppression sur-
gically seems to be the most straightforward approach to
overcome immunosuppression, additional strategies include
neutralizing TGF-b, at least transiently, or employing im-
mune adjuvants, such as granulocyte macrophage colony-
stimulating factor or toll-like receptor 2 agonists. The most
powerful combinatorial strategy for tumor-specific vaccines,
however, is likely to be the checkpoint inhibitors, as outlined
above. Such additional efforts at boosting immune re-
sponses may be essential for a benefit from upcoming
strategies of immunotherapy in broader populations of
patients, including patients with bulky disease, heavily
pretreated patients, and older patients who are likely to
exhibit impaired immune responsiveness.
CHECKPOINT INHIBITORS
An important component of tumor-induced immunosup-
pression involves the costimulatory interaction. Normally,
when a T cell encounters an antigen-presenting cell (APC)
expressing the appropriate antigen, a second interaction
with a checkpoint molecule is required to either activate or
suppress the T cell (Fig. 2).7,8 This second interaction plays
an important role in modulating an immune response.
Furthermore, there are multiple costimulatory molecules,
which suggest that a hierarchy of activation status exists. In
addition, this interaction is not unique to APCs and T cells;
other immune cells, such as natural killer cells and regulatory
T cells (Tregs), also have costimulatory molecules.8 Hence,
this suggests a hierarchy of immune cell activation as well as
an ability to attenuate an immune response.
Checkpoint inhibitors are a class of antibodies that are
designed to interrupt or activate these costimulatory mol-
ecules. Intense investigation is underway for the utilization
of checkpoint inhibitors for the treatment of solid tumors.
CTLA-4 was one of the first molecules to be studied. Leach
et al9 found that they could induce an antitumor immune
response within a murine model for melanoma by using an
anti–CTLA-4 antibody.9 The second checkpoint inhibitor that
has been intensely studied is anti–PD-1. Anti–PD-1 has been
shown to induce an antitumor immune response in multiple
solid tumors, including glioblastoma.10,11
Proven Efficacy of Checkpoint Inhibitors
Several large clinical trials in humans verified the observed
efficacy of checkpoint inhibitors in the preclinical models. In
2010, Hodi et al12 ran a large phase III trial that demonstrated
KEY POINTS
• Immunotherapy has proven efficacy for other solid
tumors and is now a focus for glioblastoma.
• An important component of glioblastoma-mediated
immunosuppression stems from soluble factors such as
TGF-b.
• Checkpoint inhibition probably confers a nonspecific
state of immune activation that is a promising approach
to glioblastoma, given the success of checkpoint
inhibitors in melanoma, lung cancer, and renal cancers.
• Current strategies for biomarkers have focused on
protein expression, immune cell characterization, and
mutational burden.
• Tumor-selective viruses and viral-based vectors have
shown increasingly promising results as easy-to-use
immunostimulants.
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improved survival among patients with melanoma who were
treated with anti–CTLA-4. The investigators also found that a
subset of patients were long-term survivors.12 Topalian et al13
then published their experience in treating multiple solid
tumors with anti–PD-1, in which they found that anti–PD-1
improved survival for patients with melanoma, renal cell
carcinoma, and non–small cell lung cancer. These and other
important studies resulted in U.S. Food and Drug Adminis-
tration (FDA) approval of checkpoint inhibitors. Checkpoint
inhibitors first gained FDA approval for use in patients with
melanoma in 2011,with the approval of anti–CTLA-4. The FDA
approved anti–PD-1 in September 2014 for melanoma.
Shortly after, anti–PD-1 was approved for lung cancer (both
adenocarcinoma and squamous cell carcinoma) and renal cell
cancer. Hence, the enthusiasm for the use of checkpoint
inhibitors in glioblastoma is high.
Checkpoint Inhibitors for Glioblastoma
There are promising preclinical data suggesting that
checkpoint inhibitors may promote an antitumor immune
response. Fecci et al14 demonstrated improved survival
mediated by a CD4+ T-cell immune response in a murine
glioma model treated with anti–CTLA-4. Zeng et al and
others have shown that anti–PD-1 monotherapy improved
survival in a murine model for glioblastoma. Interestingly,
anti–PD-L1 alone did not result in much survival im-
provement. With anti–PD-1 use, the CD8+ T cells appear to
be responsible for the antitumor immune response.10,11
CURRENT TRIALS FOR GLIOBLASTOMA
Because we observed improved survival with the use of
checkpoint inhibitors in the previously mentioned solid
tumors, these compounds are now being applied to glio-
blastoma. Several clinical trials are currently underway, with
encouraging preclinical results.
NCT02017717
NCT02017717 is a large, randomized, phase III open-label
trial sponsored by Bristol Myers Squibb for patients with a
first-time recurrence of glioblastoma that used anti–PD-1 as
the treatment backbone to assess its safety and, ultimately,
its efficacy. The study began with a small safety run-in,
during which patients were treated with anti–PD-1 alone
or anti–PD-1with anti–CTLA-4. Interim safety data that were
presented at the 2015 American Society of Clinical Oncology
Annual Meeting showed that the rates of severe adverse
events were significantly higher among patients who re-
ceived the combination of anti–PD-1 and anti–CTLA-4; 40%
of patients had to discontinue therapy (10 patients per arm).
Thus, a decision was made to expand the anti–PD-1 cohort
and to use bevacizumab as the comparator arm. Although
this was a study of safety, a partial response in one patient
who was treated with anti-PD-1 alone, and a few cases of
pseudoprogression, was observed. The trial has finished
accrual.
NCT02337491
NCT02337491 is phase II trial based on the premise that anti-
VEGF therapy could be synergistic with immunotherapy.15
This trial is a single-institution study sponsoredbyMerck using
Merck’s anti–PD-1 drug. The study will measure progression-
free survival at 6 months. The trial has two arms: anti–PD-1
alone and anti–PD-1 with bevacizumab.
NCT02336166
NCT02336166 is a phase II trial sponsored by the Ludwig
Foundation to study the anti–PD-1 therapy developed by
AstraZeneca. The trial has multiple objectives. The first
cohort (cohort A) will study the efficacy of anti–PD-L1 for
patients with newly diagnosed glioblastoma that has
unmethylated O(6)-methylguanine DNA methyltransferase.
The remarkable factor in this arm is that temozolomide
(TMZ) will be withheld; patients will receive only anti–PD-L1
and radiation. The rationale behind this design is that ra-
diation and anti–PD-L1 are synergistic, so systemic che-
motherapy may be counterproductive. The second cohort
(cohort B) will assess the efficacy of anti–PD-L1 alone for
patients who have recurrent glioblastoma. The third cohort
(cohort C) will administer anti–PD-L1 to patients who have
recurrent glioblastoma that is progressing with bevacizumab
treatment.
NCT02617589
NCT02617589 is a phase III trial sponsored by Bristol Myers
Squibb to assess the efficacy of anti–PD-1 with radiation
among patients who have newly diagnosed glioblastoma.
The comparator arm will enroll patients for treatment with
radiation and temozolomide (standard of care).
NCT02313272
NCT02313272 is a phase I trial to assess the safety of an
anti–PD-1 drug developed by Merck with bevacizumab and
hypofractionated stereotactic irradiation for patients who
have recurrent high-grade gliomas.
NCT02530502
NCT02530502 is a phase I/II trial for patients with newly
diagnosed glioblastoma. Phase I will assess the safety of
combining an anti–PD-1 drug developed by Merck with
radiation and temozolomide for patients with newly di-
agnosed glioblastoma. Phase II will compare the efficacy of
adding anti–PD-1 to radiation and temozolomide for pa-
tients treated with radiation and temolozomide.
NCT02311582
NCT02311582 is a phase I, open-label, randomized safety
study to assess the addition of MK-3475, an anti–PD-1
drug developed by Merck, for treatment among patients
who are being treated with laser ablation for recurrent
glioblastoma.
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BIOMARKERS
What we have learned from checkpoint inhibitor trials in
other tumors is that the overall response rate is between
20% and 30%. Therefore, it is important to identify patients
who would not respond and to minimize toxicities and treat
themwith other therapies. Current strategies for biomarkers
have focused on protein expression, immune cell charac-
terization, and mutational burden.
The melanoma and lung cancer trials have focused on the
expression of PD-L1 on tumor cells as a biomarker to predict
response. Investigators have found that tumors that express
PD-L1 were more likely than PD-L1–negative tumors to
respond (overall response rate) to anti–PD-1 therapy.16
Interestingly, the expression of PD-L1 was not important
in the trial of patients with melanoma who received the
concurrent combination of anti–PD-1 and anti–CTLA-4.
Some theorized that an adaptive immune response oc-
curred with the combination therapy and that combination
caused tumor cells to express PD-L1 as a defense mecha-
nism.17 In an interesting twist, when the therapies were
sequenced—patients received anti–CTLA-4 first, followed by
anti–PD-1—the overall response rate again correlated to the
PD-L1 status of the tumor.18
Another approach has been to assess the activation status
of various immune cells as a predictor of response. As an
example, investigators assessed the activation status of CD8+
T cells by measuring eomesodermin for patients with mela-
noma after they received treatment with anti–CTLA-4 and
found that the eomesodermin status predicted relapse-free
survival. Other markers of interest are interferon gamma
expression, Helios expression, and various other checkpoint
molecules.19
Last, investigators have assessed mutational burden as a
predictor of response. Chan et al20 correlated mutational
burden among patients with lung cancer to response rates
among patients who received anti–PD-1 therapy. They
found that patients with lung cancer who had a history of
smoking had higher mutational burdens than patients with
lung cancer who did not smoke and that the higher number
of mutations correlated to improved survival.20 Le et al21
also studied patients with colon cancer and found that
patients who had a defective DNA repair gene had a higher
number of mutations in their tumor, and this again corre-
lated to improved survival. Some theorize that the reason for
the observed improved antitumor immune responses in
patients with tumors that had more mutations was that
the tumors expressed a higher number of target antigens for
the immune system.21,22
TOXICITY
Immune-related toxicities are an important issue for pa-
tients who receive immunotherapy. Most of the toxicities
are related to autoimmune reactions. The most common
toxicities include colitis, pneumonitis, hepatitis, pancreatitis,
dermatitis, hypophysitis, and thyroiditis. If the toxicities are
not recognized early, these reactions could become life
threatening. Treatments often require stopping the treat-
ment, starting high-dose corticosteroids, and possibly ad-
ministering infliximab.12,13,23
IMAGING
Determining response to immunotherapy with imaging has
become an area of intense interest. In the trial reported by
Hodi et al,12 a large number of patients with melanoma who
received anti–CTLA-4 experienced pseudoprogression.
Furthermore, the researchers found that pseudoprogression
could take months to resolve.24,25 As a result, many trials
have built in lag times for imaging to allow patients to
continue therapy and to avoid considering the treatment a
failure. In glioblastoma, Okada et al26 have developed an
iRANO protocol specifically tailored for immunotherapy.
COMBINATION THERAPY
As previouslymentioned, the response rates for patientswho
receive immunotherapyhas ranged from20%to30%. Studies
are investigating ways to combine checkpoint inhibitors with
other modalities, such as radiation, bevacizumab, and de-
vices. Zeng et al10 demonstrated in a preclinical glioblastoma
model that the combination of focused radiation with
anti–PD-1 is synergistic. Clinical trials (e.g., NCT02313272) are
looking at stereotactic radiation use in combination with
checkpoint inhibitors. Bevacizumab also may work syner-
gistically with immunotherapy.20 Preclinical data suggest
that this approach could be effective, and a phase II trial
(NCT02337491) is looking at the combination of bevacizumab
and anti–PD-1 for patientswith glioblastoma. Finally, another
interesting approach is the combination of laser ablationwith
anti–PD-1. A phase I trial (NCT02313272) is looking at the
combination of anti–PD-1 with laser ablation.
In conclusion, checkpoint inhibitors have shown great
promise in other solid tumors. There is much excitement
about checkpoint inhibitors in the setting of glioblastoma.
Several large trials are underway to assess the efficacy of
checkpoint inhibitors in glioblastoma.
VIRAL- AND GENE-MEDIATED
IMMUNOTHERAPIES FOR GLIOBLASTOMA
We have discussed the various types of immunotherapy for
glioblastoma. Now, we discuss one additional mode that
involves the use of genetically engineered viruses to deliver
cytotoxic/immunostimulatory genes into tumors.27 Two
main types of viruses are used in this technology: replication-
defective vectors, inwhich viral genes have been removed so
there is no expression of viral genes or generation of progeny
viruses, but there is expression of an immunostimulatory
and/or cytotoxic gene, and tumor replication–selective vi-
ruses (oncolytic viruses), in which a viral pathogen is engi-
neered so that its pathogenicity is now targeted to tumor
cells and not normal cells.28 It is recognized now that the
presence of viral genes and viral proteins in both of these
technologies can elicit powerful anticancer immune re-
sponses, which are a major component of efficacy.29
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Characteristics that differentiate this immunotherapy
from others are the following: this immunotherapy in-
volves a neurosurgical component of direct injection into
glioblastoma, either by stereotaxy or free-hand injection
during a craniotomy; is off-the-shelf, in that manipulation of
cells from the patient before or after treatment is not in-
volved; and does not require a priori knowledge of the
identity of tumor-specific antigens that require targeting
and, at least in theory, the cytotoxic action of the viral
vector-delivered cytotoxic gene or of the replicating onco-
lytic viruses will expose the repertoire of all tumor-specific
antigens to the immune system.
There are more than 2 decades of clinical trial experiences
that used various types of replication-defective vectors to
deliver various types of cytotoxic/immunostimulatory genes,
but none have resulted in an FDA-approved clinical product,
and twophase III clinical trials—a retroviral vector todeliver the
cytotoxic/immunostimulatory herpes thymidine kinase (TK)
gene for recurrent glioblastoma30 and an adenoviral vector to
deliver TK in newly diagnosed glioblastoma (ASPECT)—have
failed.31 However,we recently reported the results of a phase II
trial in which aglatimagene besadenovec (AdV-tk), a non-
replicating adenovirus expressing the herpesvirus TK gene,
was free-hand injected in a resected, newly diagnosed, ma-
lignant glioma cavity.32,33 The patient then received the oral
antiherpetic prodrug (valacyclovir) while undergoing standard-
of-care radiochemotherapy (gene-mediated cytotoxic immu-
notherapy [GMCI]). There are multiple modes of cytotoxic and
immunostimulatory anticancer action (Fig. 3):
1. The delivered TK gene product phosphorylates the ad-
ministeredvalacyclovirdrug,whichbecomes incorporated
at sites where DNA is becoming repaired or where DNA is
replicating. This leads to termination ofDNA repair and/or
replication, leading to immunogenic cell death.
2. Standard of care also leads to cytotoxicity, and
radiation-induced DNA damage leads to additional
unsuccessful and cytotoxic attempts at DNA repair
using the phosphorylated valacyclovir pools.
3. The delivered TK antigen and viral vector proteins act
as superantigens, providing an immunostimulatory
stimulus in the glioblastoma microenvironment.
4. The cytotoxic death of glioblastoma cells is also im-
munogenic, releasing and exposing multiple glioma
antigens to the immune system.
Our published mature phase II data appear to show en-
couraging, albeit not definite, results in terms of possible
efficacy on the basis of the extent of residual tumor burden:
the median overall survival (OS) durations for patients who
underwent gross total resection were 25.0 and 16.9 months
(a difference of 8.1 months) for GMCI/standard of care
and standard of care, respectively (hazard ratio 0.59; 95%
CI, 0.35–0.998; p = .0492); for patients who underwent
subtotal resections, the difference was only 1 month (13.5
vs. 12.5 months for GMCI/standard of care vs. standard of
care; p = .4584).33 To further improve this therapy, we have
returned to the laboratory. The current theory is that to
be effective, an anticancer immune response by cytotoxic
FIGURE 1. Immunosuppressive Properties of Glioma Stem Cells
Abbreviation: TGF-b, transforming growth factor-beta.
Modified from Hatiboglu et al.42
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T cells requires removal of immune checkpoint signaling
mediated by PD-1/PD-L1,34-36 the CTLA-4/B7 family,37,38 and
othermolecules. We thus hypothesize that a combination of
GMCI and checkpoint inhibitors may lead to more effective
immunotherapy.8 In fact, we are finding that the application
of GMCI in mouse gliomas does lead to increase signaling of
immune checkpoint networks and that inhibition of these
networks does lead to even more encouraging antigliomal
effects of GMCI.
For the second type of viral-mediated therapy, multiple
types of oncolytic viruses have been tested in clinical trials of
glioblastoma, all in the recurrent setting. No trial for glio-
blastoma has progressed to phase III, but there are two
oncolytic viruses (an oncolytic adenovirus from DNAtrix
FIGURE 2. Examples of Activating (CD28) and Inhibiting (PD-1) Immune Checkpoints
FIGURE 3. Schematics of the Published Clinical Trials and DifferentModes of Anticancer Action of Gene-Mediated
Cytotoxic Immunotherapy
(Top panel) Schematic of the published clinical trials of gene-mediated cytotoxic immunotherapy (GMCI). On the day of surgery, the adenoviral vector that delivers TK (AdV-
tk) is injected in the resected newly diagnosed glioblastoma tumor cavity. The oral agent (valacyclovir) is administered to the patient on days 1 to 14. Standard-of-care
radiation and temozolomide are also administered as per the Stupp regimen. (Lower panel) Schematic of the different modes of anticancer action of GMCI.
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and an oncolytic retrovirus from Tocagen) that have
completed phase II evaluation and planning for advanced
phase III trials. Commercial interest in this area of
oncolytic virus–based immunotherapy has been resur-
rected recently by the FDA approval of a herpes simplex
virus (HSV) oncolytic virus for melanoma.29,39 Our group
has been involved in the preclinical and clinical devel-
opment of an oncolytic virus, based on HSV1, that
has been engineered to selectively replicate and de-
stroy gliomas on the basis of tumor deregulation of the
p16 tumor suppressor pathway and expression of the
glioma stem-cell marker, nestin.40,41 This oncolytic virus
(rQNestin34.5v.2) shows potency in animal models of
gliomas comparedwith older, clinical trial–tested versions
of herpes oncolytic viruses. Extensive preclinical data
have been obtained to justify filing of an investigational
new drug application with the FDA for a planned first-
in-human clinical trial among patients with recurrent
glioblastoma.
In summary, the use of tumor-selective viruses and viral-
based vectors is increasingly delivering promising results as
an easy to use immunostimulant approach, but only the
successful completion of phase III trials for several of these
products will show if the treatments have achieved their
promise as anticancer agents or if additional laboratory
development is required.
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